Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis
Open Access
- 18 November 2024
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 13 (11) , 1415
Abstract
Imeglimin promotes glucose-stimulated insulin secretion in the pancreas in a glucose-dependent manner and inhibits gluconeogenesis in the liver. Meanwhile, imeglimin can improve mitochondrial function in hepatocytes. We used a nondiabetic metabolic dysfunction-associated steatohepatitis (MASH) model to examine the effects of imeglimin on MASH independent of its glucose-lowering action. Mice fed a choline-deficient high-fat diet (CDA-HFD) were orally administered imeglimin (100 and 200 mg/kg twice daily), and MASH pathophysiology was evaluated after 8 weeks. Moreover, an in vitro study investigated the effects of imeglimin on palmitic acid (PA)-stimulated lipid accumulation, apoptosis, and mitochondrial dysfunction in human hepatocytes. CDA-HFD-fed mice showed hepatic steatosis, inflammation, and fibrosis without hyperglycemia. Imeglimin reduced hepatic steatosis in response to increased expression of β-oxidation-related markers. Imeglimin reduced reactive oxygen species accumulation and increased mitochondrial biogenesis in CDA-HFD-fed mice. Consequently, imeglimin suppressed hepatocyte apoptosis and decreased macrophage infiltration with reduced proinflammatory cytokine expression, suppressing hepatic fibrosis development. PA-stimulated hepatocytes induced lipogenesis, inflammatory cytokine production, and apoptosis, which were significantly suppressed by imeglimin. In mitochondrial function, imeglimin improved PA-stimulated decrease in mitochondrial membrane potential, mitochondrial complexes activity, oxygen consumption rate, and mitochondrial biogenesis marker expression. In conclusion, imeglimin could contribute to prevention of MASH progression through suppressing de novo lipogenesis and enhancing fatty acid oxidation.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP24K18955)
This publication has 51 references indexed in Scilit:
- The Role of Endoplasmic Reticulum in Lipotoxicity during Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) PathogenesisThe American Journal of Pathology, 2023
- Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2022
- Endoplasmic reticulum stress in liver diseasesHepatology, 2022
- The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cellsEndocrinology, Diabetes & Metabolism, 2021
- Circadian gene Clock participates in mitochondrial apoptosis pathways by regulating mitochondrial membrane potential, mitochondria out membrane permeablization and apoptosis factors in AML12 hepatocytesMolecular and Cellular Biochemistry, 2020
- Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver diseaseHepatology, 2013
- Mitochondrial ATP synthase: architecture, function and pathologyJournal of Inherited Metabolic Disease, 2011
- Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §ΔHepatology, 2010
- the Incidence and Risk Factors of Hepatocellular Carcinoma in Patients With Nonalcoholic SteatohepatitisHepatology, 2010
- AMP‐activated protein kinase suppresses LXR‐dependent sterol regulatory element‐binding protein‐1c transcription in rat hepatoma McA‐RH7777 cellsJournal of Cellular Biochemistry, 2009